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514long-term efﬁcacy of the short-term SB431542
treatment.
To investigate the mechanism by which SB431542
treatment prevents TEVG stenosis, we treated mice
from the Tie2 lineage-tracing model (n ¼ 10) with
TGFbR1 inhibitor. Drug treatment reduced the oc-
currence of EndoMT, as demonstrated by signiﬁcant
reduction in the ratio of LacZ-positive smooth muscle
cells in occluded grafts in drug-treated mice
(Figure 1B) (p < 0.05). We then explored the use of
targeted drug delivery in an attempt to maximize
efﬁcacy and minimize the risk of any drug-related
adverse events, as well as to determine whether
local drug delivery could be used to mimic the
effects of cell seeding. We developed a poly-lactic
glycolic acid microparticle–based delivery system
allowing drug release directly from the graft (5).
The drug-eluting grafts were implanted in our
mouse model (C57BL/6) (n ¼ 10). We then compared
stenosis rates to unseeded grafts with empty
microparticles (n ¼ 10) and cell-seeded grafts
(n ¼ 25) at 2 weeks. These studies showed that
the best results were achieved with microparticle
drug delivery, which completely eliminated TEVG
stenosis, while also permitting vascular neotissue
formation.
In this study, we went from the bench to the
bedside and back in an attempt to design an improved
TEVG. Clinical investigation of our ﬁrst-generation
TEVG demonstrated that the TEVG possessed
growth capacity, but its clinical utility was limited by
a high incidence of stenosis. These ﬁndings prompted
us to investigate the cellular and molecular mecha-
nisms underlying vascular neotissue formation,
which lead us to discover that excessive EndoMT
contributes to neovessel stenosis in the TEVG. We
modulated EndoMT by administration of a TGFbR1
inhibitor and showed that TGFbR1 inhibition is a
viable strategy for preventing TEVG stenosis without
blocking neovessel formation. Finally, we demon-
strated that local-controlled release of the TGFbR1
inhibitor recapitulates the functional results achieved
using cell seeding. This drug-eluting scaffold will
serve as the prototype for our second-generation
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QRS Duration in Patients
Receiving Cardiac
Resynchronization TherapyZusterzeel et al. (1) reported in the September 2, 2014,
issue of the Journal on the predictive merits of QRS
morphology and QRS duration (QRSd) following
implementation of cardiac resynchronization therapy
(CRT), analyzing 31,892 patients from the National
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515Cardiovascular Data Registry (NCDR) Implantable
Cardioverter-Deﬁbrillator registry. They found that
among patients with left bundle branch block (LBBB),
mortality is lower in women than men, but this
is not the case for patients with non-LBBB QRS
morphologies, regardless of the QRSd. In both sexes,
longer QRSd in the LBBB cohorts was associated with
lower mortality for both men and women; women
with LBBB and QRSd of 140 to 159 ms had a lower
mortality than men with similar QRS morphology and
QRSd, although this was not the case in patients with
QRSd of $150 ms.
Women have shorter QRSd than men, and this has
been often attributed to their smaller ventricles (1);
however, there is another mechanism producing
additional shortening of the QRSd, which is
dependent on QRS amplitude (QRSa) and leads to an
apparent shortening of the QRSd (2–4). Accordingly,
if QRSd is corrected for the corresponding QRSa in
the patients of the NCDR, the results might be
different than reported herein. In addition,
attributing the mortality improvement in patients
receiving CRT only to the QRS morphology (i.e.,
LBBB) and the QRSd underemphasizes the issue of
the effectiveness of the CRT, based on the appropriate
positioning of the left ventricular (LV) epicardial pacing
leads and the timing of the stimulation of the LV and
right ventricle. Regarding the later, perhaps data on the
CRT biventricular pacing-based QRSd (5), if available in
the NCDR, may enhance the value of the authors’
contribution.*John E. Madias, MD
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QRS Duration in Patients Receiving
Cardiac Resynchronization TherapyWe thank Dr. Madias for his interest in our analysis (1)
and his comments regarding QRS amplitude as well
as the role of left ventricular (LV) lead positioning
in terms of response to cardiac resynchronization
therapy (CRT). QRS amplitude could be important but
is not available in the National Cardiovascular Data
Registry (NCDR) ICD Registry, and adjustment for
QRS amplitude is not currently done in the selection
of patients for CRT. In addition, determining the
inﬂuence of QRS amplitude on QRS duration in
women and men receiving CRT is difﬁcult because
the amplitude can be inﬂuenced by multiple factors
that may also differ between sexes. We acknowledge
that, in addition to having left bundle branch
block, appropriate LV lead placement and timing of
LV stimulation is important but also not available
in the NCDR.Robbert Zusterzeel, MD
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Atrial Fibrillation and ACS
With or Without PCI
Don’t Drop Aspirin Just YetWe read with interest the review article from Dewilde
et al. (1) who nicely summarize the available evidence
on triple antithrombotic therapy in patients with atrial
ﬁbrillation (AF) undergoing coronary stenting. The
